Histopathological correlates with survival in reoperated glioblastomas

Journal of Neuro-Oncology

Volumn 113, Issue 3, 2013, Pages 485-493

  Woodworth, Graeme F ^a   Garzon Muvdi, Tomas ^b   Ye, Xiaobu ^b   Blakeley, Jaishri O ^c   Weingart, Jon D ^b   Burger, Peter C ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Glioblastoma; Pathology; Pseudoprogression; Recurrence; Treatment effect

Indexed keywords

CARMUSTINE; TEMOZOLOMIDE;

ADULT; ARTICLE; BIOPSY TECHNIQUE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; EDEMA; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; REOPERATION; RETROSPECTIVE STUDY; SALVAGE THERAPY; BRAIN NEOPLASMS; CANCER GRADING; FOLLOW UP; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REOPERATION; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84879327111     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1141-3     Document Type: Article

References (38)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996
2. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ (2004) Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63(3):535-537
3. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82(1):81-83
4. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9(5):453-461
5. Chaskis C, Neyns B, Michotte A, De Ridder M, Everaert H (2009) Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol 72(4):423-428
6. Pouleau HB, Sadeghi N, Baleriaux D, Melot C, De Witte O, Lefranc F (2012) High levels of cellular proliferation predict pseudoprogression in glioblastoma patients. Int J Oncol 40(4):923-928
7. Young RJ, Gupta A, Shah AD, Graber JJ, Zhang Z, Shi W et al (2011) Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology 76(22):1918-1924
8. Hu X, Wong KK, Young GS, Guo L, Wong ST (2011) Support vector machine multiparametric MRI identification of pseudoprogression from tumor recurrence in patients with resected glioblastoma. J Magn Reson Imaging 33(2):296-305
9. Gunjur A, Lau E, Taouk Y, Ryan G (2011) Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis. J Med Imaging Radiat Oncol 55(6):603-610
10. Gahramanov S, Raslan AM, Muldoon LL, Hamilton BE, Rooney WD, Varallyay CG et al (2011) Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys 79(2):514-523
11. Forsyth PA, Kelly PJ, Cascino TL, Scheithauer BW, Shaw EG, Dinapoli RP et al (1995) Radiation necrosis or glioma recurrence: is computer-assisted stereotactic biopsy useful? J Neurosurg 82(3):436-444
12. Topkan E, Topuk S, Oymak E, Parlak C, Pehlivan B (2012) Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide. Am J Clin Oncol 35(3):284-289
13. Bland JM, Altman DG (1998) Survival probabilities (the Kaplan-Meier method). BMJ 317(7172):1572
14. Stel VS, Dekker FW, Tripepi G, Zoccali C, Jager KJ (2011) Survival analysis I: the Kaplan-Meier method. Nephron Clin Pract 119(1):c83-c88
15. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K (2008) Chemotherapeutic wafers for high grade glioma. Cochrane Database Syst Rev 16(3):CD007294
16. Perry J, Chambers A, Spithoff K, Laperriere N (2007) Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol 14(5):189-194
17. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA et al (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113(2):405-410
18. Chamberlain MC (2008) Pseudoprogression in glioblastoma. J Clin Oncol 26(26):4359 (author reply 4359-4360)
19. Sanghera P, Perry J, Sahgal A, Symons S, Aviv R, Morrison M et al (2010) Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 37(1):36-42
20. Yaman E, Buyukberber S, Benekli M, Oner Y, Coskun U, Akmansu M et al (2010) Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. Clin Neurol Neurosurg 112(8):662-667
21. Yang I, Huh NG, Smith ZA, Han SJ, Parsa AT (2010) Distinguishing glioma recurrence from treatment effect after radiochemotherapy and immunotherapy. Neurosurg Clin N Am 21(1):181-186
22. Brandes AA, Tosoni A, Spagnolli F, Frezza G, Leonardi M, Calbucci F et al (2008) Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 10(3):361-367
23. Zhou J, Blakeley JO, Hua J, Kim M, Laterra J, Pomper MG et al (2008) Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. Magn Reson Med 60(4):842-849
24. Sanghera P, Perry J, Sahgal A, Symons S, Aviv R, Morrison M et al (2010) Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 37(1):36-42
25. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26(13):2192-2197
26. Ozdemir N, Celkan T (2010) Pseudoprogression after radiotherapy with concurrent temozolomide in a child with anaplastic astrocytoma. Pediatr Hematol Oncol 27(4):317-319
27. Pytel P, Lukas RV (2009) Update on diagnostic practice: tumors of the nervous system. Arch Pathol Lab Med 133(7):1062-1077
28. Roldan GB, Scott JN, McIntyre JB, Dharmawardene M, de Robles PA, Magliocco AM et al (2009) Population-based study of pseudoprogression after chemoradiotherapy in GBM. Can J Neurol Sci 36(5):617-622
29. Yang I, Aghi MK (2009) New advances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol 6(11):648-657
30. Gahramanov S, Raslan AM, Muldoon LL, Hamilton BE, Rooney WD, Varallyay CG et al (2011) Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys 79(2):514-523
31. Brandsma D, van den Bent MJ (2009) Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 22(6):633-638
32. Salhotra A, Lal B, Laterra J, Sun PZ, van Zijl PC, Zhou J (2008) Amide proton transfer imaging of 9L gliosarcoma and human glioblastoma xenografts. NMR Biomed 21(5):489-497
33. Zhao X, Wen Z, Huang F, Lu S, Wang X, Hu S et al (2011) Saturation power dependence of amide proton transfer image contrasts in human brain tumors and strokes at 3 T. Magn Reson Med 66(4):1033-1041
34. Zhou J, Lal B, Wilson DA, Laterra J, van Zijl PC (2003) Amide proton transfer (APT) contrast for imaging of brain tumors. Magn Reson Med 50(6):1120-1126
35. Barajas RF Jr, Chang JS, Segal MR, Parsa AT, McDermott MW, Berger MS et al (2009) Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility- weighted contrast-enhanced perfusion MR imaging. Radiology 253(2):486-496
36. Tsien C, Galban CJ, Chenevert TL, Johnson TD, Hamstra DA, Sundgren PC et al (2010) Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol 28(13):2293-2299
37. Tihan T, Barletta J, Parney I, Lamborn K, Sneed PK, Chang S (2006) Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions? Hum Pathol 37(3):272-282
38. Kim JH, Bae Kim Y, Han JH, Cho KG, Kim SH, Sheen SS et al (2012) Pathologic diagnosis of recurrent glioblastoma: morphologic, immunohistochemical, and molecular analysis of 20 paired cases. Am J Surg Pathol 36(4):620-628